iBio Inc. Annual report pursuant to Section 13 and 15(d)

Share-Based Compensation (Tables)

12 Months Ended

Jun. 30, 2020

The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Operations (in thousands):

The following table summarizes all stock option activity during the years ended June 30, 2020 and 2019:


				Weighted-
		Weighted-		average
		average		Remaining	Aggregate
	Stock	Exercise		Contractual	Intrinsic Value
	Options	Price		Term (in years)	(in thousands)
Outstanding as of July 1, 2018	1,364,583	$	12.01	4.9	$	—
Granted	400,000	$	0.90
Issued under Option Exchange	874,310	$	0.93
Forfeited/expired/exchanged	(1,292,374)	$	12.08
Outstanding as of June 30, 2019	1,346,519	$	1.45	6.1	$	—
Granted	2,383,300	$	1.11
Exercised	(139,392)	$	0.93
Forfeited/expired	(114,654)	$	3.32
Outstanding as of June 30, 2020	3,475,773	$	1.18	8.2	$	4,042
As of June 30, 2020, vested and expected to vest	3,424,064	$	1.18	8.3	$	3,987

Exercisable as of June 30, 2020	983,442	$	1.40	4.6	$	1,221

The following table summarizes information about options outstanding and exercisable at June 30, 2020:


	Options Outstanding and Exercisable
		Weighted-	Weighted-
		Average	Average
	Number	Remaining Life	Exercise		Number
	Outstanding	In Years	Price		Exercisable
Exercise prices:
$0.90 - $1.40	3,351,606	8.3	$	1.03	959,442
$1.66 - $2.49	100,333	9.9		1.667	333
$2.53 - $3.80	500	7.7		2.53	333
$7.30 - $10.95	9,334	1.9		8.59	9,334
$26.90 - $40.35	14,000	0.9		27.47	14,000
	3,475,773	8.2	$	1.18	983,442

The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:


	2020		2019
Weighted average risk-free interest rate	0.60	%	2.45	%
Dividend yield	0	%	0	%
Volatility	97.5	%	97.5	%
Expected term (in years)	9		9